Paper36980546
Progress toward Better Treatment of Therapy-Related AML.
Kotsiafti A and 3 others. Cancers (Basel), 2023. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Progress toward Better Treatment of Therapy-Related AML. Papers, record 36980546. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36980546
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References117
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29079594 | Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. | Haematologica | 2018 | https://conductscience.org/library/papers/29079594 | PubMed |
| 2 | 2530586 | Wild-type p53 can inhibit oncogene-mediated focus formation. | Proc Natl Acad Sci U S A | 1989 | https://conductscience.org/library/papers/2530586 | PubMed |
| 3 | 18286528 | Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. | Cancer | 2008 | https://conductscience.org/library/papers/18286528 | PubMed |
| 4 | 34830877 | Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34830877 | PubMed |
| 5 | 35108372 | Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. | Blood | 2022 | https://conductscience.org/library/papers/35108372 | PubMed |
| 6 | 29922294 | Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway. | Front Immunol | 2018 | https://conductscience.org/library/papers/29922294 | PubMed |
| 7 | 35063965 | Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35063965 | PubMed |
| 8 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 9 | 25757676 | Toward a better management of older patients with acute myeloid leukemia. | Future Oncol | 2015 | https://conductscience.org/library/papers/25757676 | PubMed |
| 10 | 21127174 | The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. | Blood | 2011 | https://conductscience.org/library/papers/21127174 | PubMed |
| 11 | 34492705 | Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. | Blood Adv | 2021 | https://conductscience.org/library/papers/34492705 | PubMed |
| 12 | 21039422 | Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. | Br J Pharmacol | 2011 | https://conductscience.org/library/papers/21039422 | PubMed |
| 13 | 32366443 | Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk. | Anticancer Res | 2020 | https://conductscience.org/library/papers/32366443 | PubMed |
| 14 | 1574116 | A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. | Nature | 1992 | https://conductscience.org/library/papers/1574116 | PubMed |
| 15 | 35884517 | Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35884517 | PubMed |
| 16 | 33123685 | Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. | Nat Cancer | 2020 | https://conductscience.org/library/papers/33123685 | PubMed |
| 17 | 25550361 | Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. | Blood | 2015 | https://conductscience.org/library/papers/25550361 | PubMed |
| 18 | 31203995 | Current status and new treatment approaches in TP53 mutated AML. | Best Pract Res Clin Haematol | 2019 | https://conductscience.org/library/papers/31203995 | PubMed |
| 19 | 31547736 | CPX-351 (vyxeos) in AML. | Leuk Lymphoma | 2020 | https://conductscience.org/library/papers/31547736 | PubMed |
| 20 | 17401429 | Transcription regulation by mutant p53. | Oncogene | 2007 | https://conductscience.org/library/papers/17401429 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938371 | Diagnostic and Clinical Considerations in Myeloid Neoplasms with del(5q): Distinguishing Myelodysplastic Neoplasm with Low Blasts and del(5q) from Myeloid Neoplasms with del(5q) Post-Cytotoxic Therapy. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42938371 | PubMed |
| 42835595 | Therapy-related acute myeloid leukemia with a rare complex karyotype following first-line therapy for small cell lung cancer: A case report. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42835595 | PubMed |
| 42582651 | Development of acute myeloid leukemia (AML) in two breast cancer patients undergoing treatment with long-term palbociclib: a dual case report. | Transl Breast Cancer Res | 2026 | https://conductscience.org/library/papers/42582651 | PubMed |
| 42523532 | Therapy-related myelodysplastic syndrome rapidly evolving to acute myeloid leukemia following CAR-T cell therapy in a patient with refractory diffuse large B-cell lymphoma: a case report. | Front Oncol | 2026 | https://conductscience.org/library/papers/42523532 | PubMed |
| 42239898 | Prognostic heterogeneity in ASXL1-mutated AML and refinement by an immunophenotype-based score. | Front Oncol | 2026 | https://conductscience.org/library/papers/42239898 | PubMed |
| 42063707 | Concurrent therapy-related acute myeloid leukemia and lymph node tuberculosis following treatment for lung squamous cell carcinoma: a case report and literature review. | Front Oncol | 2026 | https://conductscience.org/library/papers/42063707 | PubMed |
| 42056941 | Clinical characteristics and prognosis of therapy-related acute myeloid leukemia patients with RUNX1::RUNX1T1. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42056941 | PubMed |
| 41853304 | Therapy-related acute myeloid leukemia following successful treatment of high-risk neuroblastoma in a pediatric patient: a case report and insights into late complications. | Front Oncol | 2026 | https://conductscience.org/library/papers/41853304 | PubMed |
| 40676693 | Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/40676693 | PubMed |
| 38541635 | Recent Advances towards the Understanding of Secondary Acute Myeloid Leukemia Progression. | Life (Basel) | 2024 | https://conductscience.org/library/papers/38541635 | PubMed |
Genes89
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36980546
GET https://conductscience.org/api/papers/v1/36980546/references?page=2